All News

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

Initiating diabetes technology of any kind is a big step for patients, but also for a lot of primary care clinicians. If you have concerns, these myths and facts are for you.

The new HF guidelines prioritize primary prevention, revise disease stages to encourage early intervention, and now include SGLT2i as guideline-directed medical therapy.

To recommend, or not recommend: that is the question clinicians may ponder when considering education-focused apps for patients. Here, 5 points to help decide.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

ACC 2022: Updated findings further highlight benefit of sotagliflozin treatment in patients with T2D and CKD, regardless of cardiovascular disease presence.

Dupilumab is the only biologic to show positive, clinically meaningful phase 3 results in adults and adolescents 12 years and older with EoE.

Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.

ACC 2022. An EHR alert tailored to prompt clinicians to check guideline-directed medical therapy for individual HF patients was integrated carefully into clinical workflow.

ACC 2022. Findings suggest that more attention to monitoring cognitive functioning after a myocardial infarction is needed.

ACC 2022. Study assessed hypertension-related TikTok videos and found that 42% addressed alternative medicine, more than twice the number that focused on medical treatments.

ACC 2022. Black and Hispanic persons were 41% less likely than white individuals to receive CPR after cardiac arrest in public and 26% less likely when the event occurred in their home.

The higher dose of the GLP-1 analogue allows more flexibility for patients with T2D needing to intensify treatment, says manufacturer Novo Nordisk.

The migraine-specific oral gepants are proving effective across the continuum of migraine frequency. Dr Gottschalk talks about their shaky start.

ACC 2022. Can a couple of cups of coffee per day keep cardiovascular disease at bay? Findings from 3 new studies shed light.

ACC 2022. Approximately 5% of hospitalizations for acute MI in the state were found attributable to elevated levels of traffic noise.

ACC 2022. ACC late-breaking clinical trial sessions begin Sat, April 2, 2022. Our short slide shows highlight the studies of interest to primary care clinicians.

At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.